Evidence map›Paper›PMID 26240069›Full record

ArticleJournal of bacteriology2015

Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.

Ketaki Soparkar, Alfred D Kinana, Jon W Weeks, Keith D Morrison, Hiroshi Nikaido, Rajeev Misra

Abstract read
In one paragraph

Article in Journal of bacteriology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ketaki SoparkarSchool of Life Sciences, Arizona State University, Tempe, Arizona, USA CoValence Laboratories, Chandler, Arizona, USA.
Alfred D KinanaDepartment of Molecular and Cell Biology, University of California, Berkeley, California, USA.
Jon W WeeksSchool of Life Sciences, Arizona State University, Tempe, Arizona, USA Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma, USA.
Keith D MorrisonSchool of Earth & Space Exploration, Arizona State University, Tempe, Arizona, USA.
Hiroshi NikaidoDepartment of Molecular and Cell Biology, University of California, Berkeley, California, USA.
Rajeev MisraSchool of Life Sciences, Arizona State University, Tempe, Arizona, USA rajeev.misra@asu.edu.

Funding

BIOCHEMISTRY OF BACTERIAL CELL MEMBRANESR01AI009644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI NIKAIDO, HIROSHI · 1985 to 2015
$9.7M
BIOCHEMISTRY OF BACTERIAL CELL MEMBRANESR37AI009644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI NIKAIDO, HIROSHI · 1991 to 2000
$467k
NIAID NIH HHS AI-009644NIAID NIH HHS R01 AI009644NIAID NIH HHS R37 AI009644
6 · The paper itself

Abstract

unlabelledThe AcrB protein of Escherichia coli, together with TolC and AcrA, forms a contiguous envelope conduit for the capture and extrusion of diverse antibiotics and cellular metabolites. In this study, we sought to expand our knowledge of AcrB by conducting genetic and functional analyses. We began with an AcrB mutant bearing an F610A substitution in the drug binding pocket and obtained second-site substitutions that overcame the antibiotic hypersusceptibility phenotype conferred by the F610A mutation. Five of the seven unique single amino acid substitutions--Y49S, V127A, V127G, D153E, and G288C--mapped in the periplasmic porter domain of AcrB, with the D153E and G288C mutations mapping near and at the distal drug binding pocket, respectively. The other two substitutions--F453C and L486W--were mapped to transmembrane (TM) helices 5 and 6, respectively. The nitrocefin efflux kinetics data suggested that all periplasmic suppressors significantly restored nitrocefin binding affinity impaired by the F610A mutation. Surprisingly, despite increasing MICs of tested antibiotics and the efflux of N-phenyl-1-naphthylamine, the TM suppressors did not improve the nitrocefin efflux kinetics. These data suggest that the periplasmic substitutions act by influencing drug binding affinities for the distal binding pocket, whereas the TM substitutions may indirectly affect the conformational dynamics of the drug binding domain. IMPORTANCE: The AcrB protein and its homologues confer multidrug resistance in many important human bacterial pathogens. A greater understanding of how these efflux pump proteins function will lead to the development of effective inhibitors against them. The research presented in this paper investigates drug binding pocket mutants of AcrB through the isolation and characterization of intragenic suppressor mutations that overcome the drug susceptibility phenotype of mutations affecting the drug binding pocket. The data reveal a remarkable structure-function plasticity of the AcrB protein pertaining to its drug efflux activity.

Indexed as

Drug Resistance, Multiple, BacterialAmino Acid SubstitutionAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsBinding SitesCephalosporinsComputational BiologyEscherichia coliEscherichia coli ProteinsMutationProtein ConformationAcrB protein, E coliAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsCephalosporinsEscherichia coli Proteinsnitrocefin

Identifiers

PMID26240069
PMCPMC4573724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.